Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck, R. Kaiser, Anders Mellemgaard, +10

The Lancet Oncology

OncologyNintedanib Versus DocetaxelLume-lung 1Metronomic TherapyClinical Trials +8

Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Tony Mok, Yi‐Long Wu, Jin Soo Lee, +17

Clinical Cancer Research

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

Yi‐Long Wu, Jin Soo Lee, Sumitra Thongprasert, +27

The Lancet Oncology

OncologyMedicineMetronomic TherapyDouble-blind TrialBronchial Neoplasm +4

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Bonne Biesma, David F. Heigener, +16

Journal of Clinical Oncology

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Tony Mok, Yi‐Long Wu, Chong‐Jen Yu, +14

Journal of Clinical Oncology

Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)

Sumitra Thongprasert, Emma Duffield, Nagahiro Saijo, +11

Journal of Thoracic Oncology

Advanced NsclcOncologyCancer ManagementClinical TrialsPharmacotherapy +4

Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness

Qianjun Zhou, Qing Geng, Lin Wang, +12

EBioMedicine

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

Silvia Novello, R. Kaiser, Anders Mellemgaard, +11

European Journal of Cancer

Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer

Meilin Liao, Huimin Wang, Zhen-Qiong Lin, +2

Lung Cancer

Other Biological PredictorsAngiogenesisMedicinePostoperative Survival RatePathology +8

Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China

Yi‐Long Wu, Da‐Tong CHU, Baohui Han, +8

Asia-Pacific Journal of Clinical Oncology